ABBV
Europe just nudged the door open
AbbVie’s RINVOQ is back in the spotlight, and this time the European Medicines Agency’s CHMP is the one doing the nodding. The committee adopted a positive opinion recommending upadacitinib for adults and adolescents with severe alopecia areata — which is pharma-speak for “the drug is one bureaucratic hurdle closer to a bigger market.”
Why investors care
This isn’t a revenue print or a dramatic trial moonshot. But label expansions are the quiet little compounding machines of biotech and big pharma. If the approval follows through, AbbVie gets a shot at more patients, more prescriptions, and more life for a drug it already knows how to sell.
The company says the decision is backed by Phase 3 UP-AA data, where upadacitinib hit the primary endpoint and key secondary ones too — including eyebrow and eyelash improvements at week 24. Even better for the buzz: AbbVie says it’s the first JAK inhibitor to hit complete scalp hair regrowth (SALT = 0) at week 24 in this setting.
The fine print, pharma edition
A positive CHMP opinion is not the final trophy case moment, but it’s often the part where the finish line starts looking very real. For AbbVie, that means another potential boost for RINVOQ, a drug family that keeps trying to become the Swiss Army knife of immunology.
Big picture: AbbVie doesn’t need every approval to be flashy. It just needs enough of these incremental wins to keep the RINVOQ story chunky, durable, and very investor-friendly.